Manfred Birchler

Title: Manfred Birchler: Innovator in Scintigraphy and Angiogenesis Treatment

Introduction

Manfred Birchler is a notable inventor based in Zurich, Switzerland. He has made significant contributions to the field of medical diagnostics and treatment, particularly in the area of angiogenesis. His innovative work has led to the development of specific binding molecules that have the potential to revolutionize how new blood vessels are detected and treated.

Latest Patents

Birchler holds a patent for "Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis." This invention relates to antibodies with sub-nanomolar affinity specific for a characteristic epitope of the ED-B domain of fibronectin, which is a marker of angiogenesis. The patent also covers the use of radiolabelled high affinity anti ED-B antibodies for detecting newly forming blood vessels in vivo, along with a diagnostic kit that includes said antibody. Additionally, it discusses conjugates that comprise these antibodies and suitable photoactive molecules, which can be used for the selective light-mediated occlusion of new blood vessels.

Career Highlights

Manfred Birchler is affiliated with the Swiss Federal Institute of Technology Zurich, where he continues to engage in groundbreaking research. His work has not only advanced scientific understanding but has also paved the way for new therapeutic methods in treating conditions related to angiogenesis.

Collaborations

Birchler has collaborated with esteemed colleagues such as Dario Neri and Lorenzo Tarli. These partnerships have further enriched his research and contributed to the development of innovative solutions in the medical field.

Conclusion

Manfred Birchler's contributions to the field of scintigraphy and angiogenesis treatment exemplify the impact of innovative thinking in medicine. His patent and ongoing research hold promise for future advancements in diagnostic and therapeutic techniques.